Ann: IHL-42X positive phase 2 clinical trial results, page-33

pivotal clinical trials to commence after opening an IND with FDA. strap in we are going to market! This meeting will guide on what data is required to open an Investigational New Drug
(IND) application with FDA for IHL-42X for treatment of OSA and the design of a larger pivotal phase 2
a clinical trial with trial sites in the United States.

The Board of Directors has progressed its initiative to offer a bonus option entitlement to both reward
shareholders and provide additional funding for the Company in the future. The terms of this
entitlement offer will be finalized imminently and announced to ASX.